![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
![[thumbnail of 15338oa.pdf]](https://edoc.mdc-berlin.de/style/images/fileicons/application_pdf.png) |
PDF
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
557kB |
| Item Type: | Article |
|---|---|
| Title: | Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naive patients with mild-to-moderate Alzheimer's disease |
| Creators Name: | Peters, O., Fuentes, M., Joachim, L.K., Jessen, F., Luckhaus, C., Kornhuber, J., Pantel, J., Huell, M., Schmidtke, K., Ruether, E., Moeller, H.J., Kurz, A., Wiltfang, J., Maier, W., Wiese, B., Froelich, L. and Heuser, I. |
| Abstract: | Introduction: Several studies have tested the N-methyl-D-aspartate–receptor antagonist memantine as an add-on to pre-existing treatment with acetylcholinesterase inhibitors. The objective of this study was to evaluate the efficacy and safety of a combined memantine and galantamine-CR de novo regimen compared with galantamine-CR only treatment in never treated patients with mild-to-moderate Alzheimer's disease (AD). Methods: Antidementia drug–naïve participants (n = 232) with probable, mild-to-moderate AD, and mini-mental state examination scores between 15 and 26 (inclusive) were randomized to receive either 20 mg/day memantine plus 24 mg/day galantamine-CR or 24 mg/day galantamine-CR plus placebo in a 52-week, prospective, double-blind, controlled trial. The primary outcome measurement was the change on the Alzheimer's disease assessment scale-cognition score. Secondary measures comprised the Alzheimer's Disease Cooperative Study-activities of daily living inventory and the clinical dementia rating. Results: At the end of the trial, there were no statistically significant differences between the galantamine-CR/memantine combination and galantamine-CR only group in primary and secondary outcome measurements. The incidence and the severity of adverse events were similar between the groups. Discussion: In this trial, memantine in combination with galantamine-CR did not show an advantage with respect to cognition, function, and behavior in previously never treated patients with mild-to-moderate AD. There were no significant differences in tolerability and safety between the groups. Thus, a de novo combination treatment results in no significant improvement in disease progression (current controlled trials number: NCT01921972). |
| Keywords: | Memantine, Galantamine-CR, Combination Treatment, Acetylcholinesterase Inhibitor, Alzheimer's Disease, Dementia |
| Source: | Alzheimer's and Dementia |
| ISSN: | 1552-5260 |
| Volume: | 1 |
| Number: | 3 |
| Page Range: | 198-204 |
| Date: | November 2015 |
| Official Publication: | https://doi.org/10.1016/j.trci.2015.10.001 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
